Title: Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies

Authors: Midori Tanaka, MD1,2; Hidehito Horinouchi, MD, PhD1; Yasushi Goto, MD, PhD1; Shintaro Kanda, MD, PhD1; Yutaka Fujiwara, MD, PhD1; Hiroshi Nokihara, MD, PhD1; Noboru Yamamoto, MD, PhD1; Yuichiro Ohe, MD, PhD1

Affiliation:
1) Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
2) Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine

Corresponding author
Hidehito Horinouchi
Department of Thoracic Oncology, National Cancer Center Hospital
Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan
Telephone: +81-3-3542-2511
Fax: +81-3-3542-3815
E-mail: hhorinou@ncc.go.jp

Key words: cisplatin, short hydration, nephrotoxicity, creatinine, thoracic malignancies

Text word count (excluding references): 2246 words
Abstract

Background: Conventional hydration (CH) in chemotherapy containing cisplatin (CDDP) has been recommended to prevent renal toxicity. Although an increasing number of studies have demonstrated the feasibility of short hydration (SH), few large studies have reported the superiority of SH, compared with CH, in terms of nephrotoxicities.

Methods: We conducted a consecutive retrospective analysis of 467 patients who had been treated with chemotherapy including CDDP. Statistical analyses were performed to evaluate the risk factors for nephrotoxicities. The following factors were included in the analyses: age, sex, performance status (PS), concomitant thoracic radiotherapy, CDDP dose, magnesium supplementation, baseline creatinine values, and method of hydration.

Results: The patients' characteristics were as follows: male/female, 323/144 patients; median age (range), 62 (27-69) years; PS 0/1/2/3, 238/217/10/2 patients; and SH/CH, 111/356 patients. The proportion of patients requiring a CDDP dose reduction in the SH group was 6.3%, while that in the CH group was 12.9%. Patients who discontinued CDDP because of nephrotoxicities accounted for 0.9% of the patients in the SH group and 2.2% of the patients in the CH group. After CDDP-based chemotherapy, a creatinine increase of more than Grade 1 was observed in 14.4% and 33.1% of the patients in the SH and
CH groups, respectively. A logistic regression analysis revealed a significantly lower incidence of Grade 1 or higher creatinine toxicity after the first cycle of chemotherapy in the SH group (OR, 0.20; 95% confidence interval, 0.06-0.63; $P = 0.006$).

**Conclusions:** SH resulted in a significantly lower incidence of nephrotoxicity.
Key questions

· What is already known about this subject?

Nephrotoxicity is the main dose-limiting cisplatin-induced adverse events. To prevent cisplatin-induced renal toxicity, several strategies including magnesium supplementation, and forced diuresis have been reported and introduced to daily practice.

· What does this study add?

We conducted a consecutive retrospective analysis of 467 patients who had been treated with chemotherapy including cisplatin. We found that patients with short hydration illuminated a significantly lower frequency and severity of nephrotoxicity than those who with conventional hydration. Short hydration not only makes cisplatin use more convenient by minimizing the hydration volume and duration, but it also reduces nephrotoxicity, compared with conventional hydration.

· How might this impact on clinical practice?

This study has important implications for practical recommendations regarding optimal hydration methods for the prophylactic management of nephrotoxicity.
Introduction

Cisplatin (CDDP) continues to play a crucial role in cytotoxic chemotherapy for patients with solid tumors including lung cancer (1)(2)(3). The management of gastrointestinal and renal toxicities has been an important issue concerning the use of CDDP. Based on early phase trials, continuous and high-volume hydration has been recommended to prevent nephrotoxicity in patients who receive CDDP (4). Novel antiemetics, such as 5-HT₃ receptor and neurokinin-1 (NK-1) receptor antagonist, have dramatically improved the management of gastrointestinal toxicities associated with CDDP, leading to adequate oral intake (5). Several single-arm prospective trials have shown the safety of short-term and lower volume hydration (short hydration) using up-to-date antiemetics (6)(7). Recently, a short hydration (SH) regimen has been introduced to daily clinical practice in Japan, and an increasing number of clinical studies have demonstrated the feasibility of SH. However, only a few large analyses have compared SH with conventional hydration (CH) under up-to-date antiemetics management involving 5-HT₃ receptor, NK-1 receptor antagonist and dexamethasone. We retrospectively compared the frequency and severity of nephrotoxicity between patients receiving SH and those receiving CH among patients with thoracic malignancies that were treated with CDDP.
Patients and methods

Patients

We conducted a consecutive retrospective analysis of patients with thoracic malignancies who had been treated with chemotherapy or chemoradiotherapy including CDDP at a dose of $\geq 60 \text{ mg/m}^2$ between December 2009 and December 2013 at the National Cancer Center Hospital, Tokyo, Japan. Patients eligible for inclusion in this study were between the ages of 20 and 69 years. All the patients received aprepitant, a 5-HT3 blocker, and dexamethasone based on clinical guidelines for the management of gastrointestinal toxicities (8)(9). Horinouchi et al. conducted a prospective trial examining the safety of SH (6). After the trial, the hydration regimen shifted away from CH to SH (December 2009 to July 2013 and August 2013 to December 2013, respectively). This retrospective analysis was approved by the institutional review board.

Nephrotoxicity

We assessed nephrotoxicity using three methods: the serum creatinine value, the creatinine clearance (Ccr), and the estimated glomerular filtration rate (eGFR). An abnormal serum creatinine value was defined as higher than the upper limit of the serum creatinine level of 1.1 and 0.8 mg/dL for men and women, respectively. The Ccr
was calculated using the Cockcroft-Gault equation, and the eGFR was adjusted for the Japanese population based on the serum creatinine levels. We collected laboratory data before the start of treatment, before the second course of chemotherapy, and after the completion of the last chemotherapy treatment.

**Treatment**

All the cases received aprepitant, a 5-HT₃ blocker, and dexamethasone. As a general antiemetic premedication, palonosetron (0.75 mg) and dexamethasone (9.9 mg) were infused, and oral apreplant (125 mg on Day 1, 80 mg on Days 2–3) and dexamethasone (8 mg, Days 2–4) were administered before the start of chemotherapy. Examples of the hydration methods used in our hospital are shown in Figure 1. In the CH group, pre-hydration and post-hydration for CDDP consisted of 1000 mL of intravenous fluids each infused over a period of four hours. A total volume of 3200–3600 mL of fluid was infused over 12 hours on day 1, and 1000–2000 mL of fluid was infused each day thereafter for at least 3 days. In the SH group, patients were given 500 mL of intravenous fluids infused over a period of one hour immediately before and after CDDP administration. Hydration was administered only on day 1, with a total of 1550–2050 mL of fluid being infused over a period of 4 hours. Mannitol was used between pre-hydration and CDDP
administration during SH, whereas the diuretic was administered 3 hours after CDDP administration in the CH group. Potassium chloride was supplemented in both methods. Some patients in the CH group were not treated with magnesium sulfate. Both methods were performed in an inpatient setting.

Statistical analyses

A logistic regression analysis was conducted to assess the impact of multiple clinical factors upon an abnormal creatinine value after the first cycle of CDDP. The predictive factors included were as follows: age, sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS), concomitant thoracic radiotherapy, CDDP dose, magnesium supplementation, baseline serum creatinine level, and the method of hydration. A $P$ value of $<0.05$ was regarded as being statistically significant. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Tumor response analyses were conducted for patients with stage IIIB and IV (recurrence or metastatic) non-small cell lung cancer (NSCLC) using the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0. We assessed PFS and OS in patients with stage IIIB or IV NSCLC without an $EGFR$ mutation or $ALK$ rearrangement. The PFS period was defined as the date from the start of CDDP administration until disease progression.
or death. The OS period was defined as the interval between the date of the first administration of CDDP and death or the date of the last follow-up for patients who were alive at the end of the study period. Living patients without an event were censored as of the date of the most recent visit. All the statistical analyses were conducted using STATA version 15 (College Station, TX, USA).

Results

Patient characteristics

A total of 467 patients were analyzed in this study: 356 patients in the CH group, and 111 patients in the SH group. The median age was 62 years (range, 27-69 years). The patients’ characteristics are shown in Table 1. There were no differences in the proportions of sex, age and PS between the two groups. CDDP was administered with vinorelbine, pemetrexed, irinotecan, etoposide, docetaxel, gemcitabine or amrubicin. The proportions of adenocarcinoma (74.8% vs. 57.5%), pemetrexed administration (47.8% vs. 26.7%), and magnesium supplementation (99% vs. 82.9%) were higher in the SH group.

Nephrotoxicity
The changes in the serum creatinine, Ccr, and eGFR values in each group are summarized in Table 2. Figure 2 shows dot plots describing the renal function of all the patients at pretreatment and after the first and last cycle. The serum creatinine levels before chemotherapy were not significantly different between the two groups. After the first cycle, the proportion of patients with a creatinine increase of more than Grade 1 was 3.6% in the SH group, compared with 13.5% in the CH group. After the last cycle, the proportions of patients with a creatinine increase of more than Grade 1 were 14.4% and 33.1% in the SH and CH groups, respectively. After the first cycle, the incidence of a creatinine elevation of more than Grade 2 was 0% in the SH group, compared with 0.9% in the CH group. After the last cycle, the incidence of a creatinine elevation of more than Grade 2 was 0% in the SH group, compared with 4.2% in the CH group. A lower rate of nephrotoxicity in the SH group was also observed when the Ccr and eGFR levels were compared between the two groups. A logistic regression analysis revealed a significantly lower incidence of Grade 1 or higher abnormal creatinine levels after the first cycle of CDDP-based chemotherapy in the SH group (OR, 0.19; 95% confidence interval, 0.06-0.61; \( P = 0.006 \)) (Table 3).

_Treatment delivery_
The median number of treatment cycles was four (range, one to six cycles) in both treatment groups (Table S1). The proportion of patients requiring a dose reduction of CDDP in the CH group was 12.9%, while that in the SH group was 6.3%. The proportion of CDDP discontinuation because of nephrotoxicity was 2.2% in the CH group and 0.9% in the SH group. The proportion of patients who received intravenous hydration because of renal toxicity was 6.7% in the CH group and 1.8% in the SH group. Patients with advanced and post-surgical recurrent NSCLC who received second-line treatment accounted for 74.7% of the patients in the CH group and 82.0% of the patients in the SH group. The percentage of patients who received maintenance pemetrexed treatment after CDDP and pemetrexed was 55.6% in the CH group and 58.7% in the SH group. The mean hospital stay for a course of chemotherapy including CDDP and pemetrexed was 10.3 days for the CH group and 6.8 days for the SH group. The SH group had a shorter period of hospitalization.

Response and survival

The treatment efficacies in patients with advanced NCLC (n = 153) are shown in Table S2. The overall response rate (ORR) was 37.5% in the SH group and 34.0% in the CH group. No significant difference was seen between the two groups. The Kaplan–Meier
curves for PFS and OS are shown in Figure 3. Among the patients with stage IIIB or IV NSCLC without an *EGFR* mutation or *ALK* rearrangement (n = 88), a total of 27 patients in the SH group and 61 in the CH group were included in the survival analysis. The median PFS was 5.2 months and 6.2 months (hazard ratio [HR], 0.98; 95% CI, 0.59-1.63) and the median OS was 16.1 months and 19.0 months (HR, 1.00; 95% CI, 0.58-1.73) for the SH and CH groups, respectively. No significant difference in survival was seen between the two groups.

**Discussion**

This retrospective study evaluated the effectiveness of SH for CDDP-based chemotherapy compared with CH in patients aged 70 years or younger. We found that patients treated with SH had a significantly lower frequency and severity of nephrotoxicity than those treated with CH. To our knowledge, our sample size is the largest retrospective analysis to compare two types of hydration methods.

CDDP-induced nephrotoxicity has been attributed to the accumulation of CDDP in renal tubules and associated tubular cell necrosis, particularly in the proximal tubules in the outer renal medulla in the S3 segment (10). Moreover, a reduction in Ccr after CDDP administration is correlated with the peak plasma level of platinum (11). Therefore,
saline hydration and forced diuresis using mannitol or furosemide are crucial for preventing nephrotoxicity, and hydration for more than 24 hours after the introduction of CDDP has been conventionally performed. However, CDDP exhibits unique pharmacokinetics in that the plasma concentration of protein-unbound platinum reaches its peak just after intravenous administration and is cleared to below a measurable level within the first 2 hours following CDDP administration (12). Furthermore, Stewart et al. assessed the effects of various factors on elevated serum creatinine levels in 425 patients treated with CDDP and suggested that the amount of hydration had no effect on the incidence of renal dysfunction (13). These features and reports suggest the significance of rapid and short-term hydration for the prevention of nephrotoxicity, with long-term and high-volume hydration possibly being unnecessary. Additionally, the importance of magnesium supplementation for the prevention of CDDP nephrotoxicity has also been highlighted. Hypomagnesemia causes dehydration and the up-regulation of rat organic cation transporter 2 (OCT2), which plays a role in urinary excretion and the uptake of CDDP in the proximal tubules (14), thereby increasing the renal accumulation of CDDP (15).

In 2007, Tiseo et al. conducted a retrospective study showing the feasibility of SH in CDDP-based chemotherapy using magnesium supplementation and forced diuresis for
the treatment of lung cancer and mesothelioma (16). Three different single-arm prospective trials also concluded that SH is safe and feasible (17) (18) (19). Several other retrospective analyses have compared SH with CH. An analysis of 143 patients reported by Sakaida et al. showed that the incidence of an elevated serum creatinine level of ≥Grade 1 was 3.8% in an SH group and 21.0% in a CH group. In their study, the administration of mannitol as a diuretic and magnesium supplementation were only performed in the SH group (20). In the presently reported study, 467 patients divided into two groups received the same antiemetics and mannitol treatment, and most of the patients also received magnesium supplementation. Nevertheless, a significant difference in the incidence of renal toxicity was observed between the two methods of hydration.

In terms of treatment efficacy, the response and survival rates in this study were consistent with previously reported data (3. The ORR, PFS and OS were not significantly different between the SH and CH groups. We found that the treatment efficacy was maintained even when the SH method was used.

The present study had some limitations. Because it was a retrospective and non-randomized analysis, there were some imbalances in clinical factors, such as histology and the administration of other anticancer drugs in combination with CDDP. However,
to minimize potential biases in patient selection, patients in both groups were enrolled consecutively irrespective of their medical background (e.g., renal function) or treatment (e.g., dose of CDDP).

**Conclusion**

Short hydration resulted in a significantly lower incidence of nephrotoxicity than conventional hydration. To reduce nephrotoxicity in cisplatin-containing regimens, short hydration should be recommended.

**Acknowledgments**

This study was presented at ESMO Asia 2015 Congress.

**References**

1. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer. New England Journal of Medicine 2002;346(2):85–91.

2. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer. New England Journal of Medicine
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2008;26(21):3543–51.

4. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39(4):1372–81.

5. Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Annals of Oncology 2013;24(4):1067–73.

6. Horinouchi H, Kubota K, Itani H, et al. Short Hydration in Chemotherapy Containing Cisplatin (≥75 mg/m2) for Patients with Lung Cancer: A Prospective Study. Japanese Journal of Clinical Oncology 2013;43(11):1105–9.

7. Hotta K, Takigawa N, Hisamoto-Sato A, et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Japanese Journal of Clinical Oncology 2015;45(6):603–4.
8. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Annals of Oncology 2010;21(Supplement 5):v232–v243.

9. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. Journal of Clinical Oncology 2006;24(18):2932–47.

10. Dobyan DC, Levi J, Jacobs C, et al. Nephrotoxicity mechanism of cis-platinum (II) diamine dichloride in mice. J Pharmacol Exp Ther 1994;71(2):161–8.

11. Reece PA, Stafford I, Russell J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. Journal of Clinical Oncology 1987;5(2):304–9.

12. Sasaki Y, Tamura T, Eguchi K, et al. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 1989;23(4):243–6.

13. Stewart DJ, Dulberg CS, Mikhael NZ, et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother
14. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity. Clin Pharmacol Ther 2009;86(4):396–402.

15. Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 2009;13(6):578–84.

16. Tiseo M, Martelli O, Mancuso A, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007;93(2):138–44.

17. Okazaki S, Nakajima TE, Hashimoto J, et al. Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. Japanese Journal of Clinical Oncology 2013;43(11):1115–23.

18. Okazaki S, Nakajima TE, Hashimoto J, et al. A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer. Gastric Cancer 2012;16(1):41–7.

19. Ninomiya K, Hotta K, Hisamoto-Sato A, et al. Short-term low-volume hydration in
cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 2015;21(1):81–7.

20. Sakaida E, Iwasawa S, Kurimoto R, et al. Safety of a short hydration method for cisplatin administration in comparison with a conventional method—a retrospective study. Japanese Journal of Clinical Oncology 2016;46(4): hyv203–377.

Tables

Table 1. Patient characteristics

Table 2. Sequential evaluations of renal function

Table 3. Evaluation of predictors of an abnormal creatinine value after the first cycle of cisplatin-based chemotherapy (logistic regression analysis)

Figure legends

Figure 1. Examples of the chemotherapy regimen.

Figure 2. Dot plots comparing changes in renal function at pretreatment and after the first and last cycles in both hydration groups.

Figure 2-A. Serum creatinine level in the conventional hydration group.

Figure 2-B. Serum creatinine level in the short hydration group.
Figure 2·C. Creatinine clearance in the conventional hydration group.

Figure 2·D. Creatinine clearance in the short hydration group.

Figure 2·E. eGFR in the conventional hydration group.

Figure 2·F. eGFR in the short hydration group.

Figure 3. Kaplan-Meier Estimates of progression-free survival and overall survival.

Supplementary tables

Table S1. Treatment delivery

Table S2. Response rates for patients with stage IIIB, IV or post-surgical recurrences of NSCLC
Table 1. Patient characteristics

|                               | Conventional hydration | Short hydration |
|-------------------------------|------------------------|-----------------|
|                               | n = 356 % or range     | n = 111 % or range |
| Age (years)                   |                        |                 |
| Median (range)                | 61 27-69               | 63 33-69        |
| Sex                           |                        |                 |
| Female                        | 108 30.3               | 36 32.4         |
| Male                          | 248 69.7               | 75 67.6         |
| Performance status            |                        |                 |
| 0                             | 188 52.8               | 50 45.1         |
| 1                             | 158 44.3               | 59 53.1         |
| 2                             | 8 2.3                  | 2 1.8           |
| 3                             | 2 0.6                  | 0 0             |
| Treatment setting             |                        |                 |
| Advanced disease              | 152 42.7               | 58 52.3         |
| Chemoradiotherapy             | 104 29.2               | 23 20.7         |
| Adjuvant therapy              | 66 18.5                | 21 18.9         |
| Post-surgical recurrence      | 34 9.6                 | 9 8.1           |
| Treatment regimen                        | Count | Percent | Median | IQR   |
|-----------------------------------------|-------|---------|--------|-------|
| Cisplatin + Vinorelbine                 | 137   | 38.4    | 38     | 34.2  |
| Cisplatin + Pemetrexed                  | 95    | 26.7    | 53     | 47.8  |
| Cisplatin + Irinotecan                  | 58    | 16.3    | 4      | 3.6   |
| Cisplatin + Etoposide                   | 30    | 8.4     | 4      | 3.6   |
| Cisplatin + Docetaxel                   | 26    | 7.3     | 7      | 6.3   |
| Cisplatin + Gemcitabine                 | 8     | 2.3     | 5      | 4.5   |
| Cisplatin + Amrubicin                   | 2     | 0.6     | 0      | 0     |

| Histology                              |       |         |       |       |
|----------------------------------------|-------|---------|-------|-------|
| Adenocarcinoma                         | 204   | 57.5    | 83    | 74.8  |
| Squamous cell carcinoma                | 42    | 11.8    | 16    | 14.4  |
| NSCLC*1                                | 14    | 3.9     | 4     | 3.6   |
| Small cell carcinoma                   | 73    | 20.6    | 5     | 4.5   |
| LCNEC*2                                | 14    | 3.9     | 3     | 2.7   |
| MPM*3                                  | 8     | 2.3     | 0     | 0     |

| Comorbidities                          |       |         |       |       |
|----------------------------------------|-------|---------|-------|-------|
| Hypertension                           | 98    | 27.5    | 25    | 22.5  |
| Diabetes mellitus                      | 20    | 5.6     | 2     | 1.8   |
| Condition                                | Value | Percentage | Mean | Median |
|-----------------------------------------|-------|------------|------|--------|
| Cardiac disease                         | 17    | 4.8        | 0    | 0      |
| Pulmonary disease                       | 43    | 12.1       | 13   | 11.7   |
| Magnesium supplementation               | 295   | 82.9       | 110  | 99.0   |

*1 Non-small cell lung cancer (not otherwise specified and other NSCLC)

*2 Large-cell neuroendocrine carcinoma

*3 Malignant pleural mesothelioma
Table 2. Sequential evaluations of renal function

|                      | Conventional hydration | Short hydration |
|----------------------|------------------------|-----------------|
|                      | Before treatment       | After first cycle | After last cycle | Before treatment | After first cycle | After last cycle |
| Creatinine elevation |                        |                  |                  |                  |                  |                  |
| (n, %)               |                        |                  |                  |                  |                  |                  |
| Grade 0              | 344 (96.6)             | 308 (86.5)       | 238 (66.9)       | 107 (96.4)       | 107 (96.4)       | 95 (85.6)        |
| Grade 1              | 12 (3.4)               | 45 (12.6)        | 103 (28.9)       | 4 (3.6)          | 4 (3.6)          | 16 (14.4)        |
| Grade 2 *            | 0 (0)                  | 3 (0.9)          | 15 (4.2)         | 0 (0)            | 0 (0)            | 0 (0)            |
| Serum creatinine (mg/dL) |                    |                  |                  |                  |                  |                  |
| Median               | 0.7                    | 0.76             | 0.80             | 0.7              | 0.75             | 0.79             |
| Range                | 0.37-1.3               | 0.37-2.5         | 0.37-2.5         | 0.4-1.1          | 0.4-1.3          | 0.4-1.6          |
| Ccr*2 (mL/min)       |                        |                  |                  |                  |                  |                  |
| Median               | 92.4                   | 83.6             | 73.2             | 93.1             | 87.2             | 82.1             |
| Range                | 44.2-253.7             | 30.3-240.6       | 27.0-216.9       | 49.4-173.2       | 42.9-153.2       | 38.1-176.1       |
| eGFR*3 (mL/min/1.73 m²) |                    |                  |                  |                  |                  |                  |
| Median               | 85.0                   | 76.0             | 65.3             | 80.8             | 77.5             | 73.7             |
| Range                | 43.4-198.3             | 22.2-167.4       | 22.2-167.4       | 53.0-126.1       | 44.1-141.7       | 36.9-141.7       |
*1 Maximum grade of creatinine elevation according to the National Cancer Institute Common Toxicity Criteria (CTCAE), version 4.0

*2 Calculated creatinine clearance using the Cockcroft-Gault equation, mL/min

*3 Estimated glomerular filtration rate using the Japanese equations for estimating the glomerular filtration rate from the serum Cr level, mL/min/1.73 m²
Table 3. Evaluation of predictors of an abnormal creatinine value*1 after the first cycle of cisplatin-based chemotherapy (logistic regression analysis)

| Predictor                        | Univariate | Multivariate |
|---------------------------------|------------|--------------|
|                                 | OR 95% C.I. | P value      | OR 95% C.I. | P value |
| Age (years)                     |            |              |            |         |
| <62                             | 1          | 1            | 1          |         |
| ≥62                             | 1.43 0.79-2.57 0.234 |            | 1.70 0.89-3.26 0.109 |         |
| Sex                             |            |              |            |         |
| Female                          | 1          | 1            | 1          |         |
| Male                            | 1.00 0.54-1.87 0.991 |            | 1.27 0.61-2.63 0.528 |         |
| Performance status              |            |              |            |         |
| 0-1                             | 1          | 1            | 1          |         |
| 2-3                             | 0.72 0.09-5.69 0.756 |            | 1.04 0.12-8.78 0.968 |         |
| Chemoradiotherapy               |            |              |            |         |
| No                              | 1          | 1            | 1          |         |
| Yes                             | 2.34 1.30-4.23 0.005 |            | 2.50 1.26-4.96 0.009 |         |
| Dose of cisplatin               |            |              |            |         |
| 60 mg/m²                        | 1          | 1            | 1          |         |
| 75 or 80 mg/m² | 1.95 | 0.68-5.61 | 0.216 | 2.03 | 0.60-6.87 | 0.255 |

Magnesium supplementation

| No | 1 | 1 |
| Yes | 1.91 | 0.93-3.96 | 0.080 | 1.63 | 0.73-3.65 | 0.230 |

Baseline creatinine value

| Normal | 1 | 1 |
| Abnormal*¹ | 16.2 | 5.62-46.9 | <0.001 | 30.5 | 8.87-104 | <0.001 |

Method of hydration

| Conventional hydration | 1 | 1 |
| Short hydration | 0.24 | 0.08-0.68 | 0.007 | 0.19 | 0.06-0.61 | 0.006 |

*¹ Creatinine value higher than the upper limit of the creatinine value.
Figure 1. Examples of the chemotherapy regimen
Figure 2: Dot plots comparing changes in renal function at pretreatment and after the first and last cycles in both hydration groups. (A) Serum creatinine level in the conventional hydration group; (B) Serum creatinine level in the short hydration group; (C) Creatinine clearance in the conventional hydration group; (D) Creatinine clearance in the short hydration group; (E) eGFR in the conventional hydration group; (F) eGFR in the short hydration group.
Figure 3. Kaplan–Meier Estimates of Progression-free Survival and Overall Survival.